Cl-HOBtCAS# 26198-19-6 |
- Narciclasine
Catalog No.:BCN4732
CAS No.:29477-83-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 26198-19-6 | SDF | Download SDF |
PubChem ID | 232711 | Appearance | Powder |
Formula | C6H4ClN3O | M.Wt | 169.6 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 6-chloro-1-hydroxybenzotriazole | ||
SMILES | C1=CC2=C(C=C1Cl)N(N=N2)O | ||
Standard InChIKey | TZCYLJGNWDVJRA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C6H4ClN3O/c7-4-1-2-5-6(3-4)10(11)9-8-5/h1-3,11H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Cl-HOBt Dilution Calculator
Cl-HOBt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.8962 mL | 29.4811 mL | 58.9623 mL | 117.9245 mL | 147.4057 mL |
5 mM | 1.1792 mL | 5.8962 mL | 11.7925 mL | 23.5849 mL | 29.4811 mL |
10 mM | 0.5896 mL | 2.9481 mL | 5.8962 mL | 11.7925 mL | 14.7406 mL |
50 mM | 0.1179 mL | 0.5896 mL | 1.1792 mL | 2.3585 mL | 2.9481 mL |
100 mM | 0.059 mL | 0.2948 mL | 0.5896 mL | 1.1792 mL | 1.4741 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Reagent to suppress racemization in peptide coupling, which is not toxic.
- CALP3
Catalog No.:BCC5900
CAS No.:261969-05-5
- CALP2
Catalog No.:BCC5898
CAS No.:261969-04-4
- Isotaxiresinol
Catalog No.:BCN4660
CAS No.:26194-57-0
- SB269970 HCl
Catalog No.:BCC5056
CAS No.:261901-57-9
- Foliamenthoic acid
Catalog No.:BCN5138
CAS No.:26187-80-4
- 6-Prenylsakuranetin
Catalog No.:BCN7883
CAS No.:261776-61-8
- 6-Methyl-8-prenylnaringenin
Catalog No.:BCN6860
CAS No.:261776-60-7
- 3,19-Dihydroxy-6,23-dioxo-12-ursen-28-oic acid
Catalog No.:BCN1471
CAS No.:261768-88-1
- Beesioside Q
Catalog No.:BCC8301
CAS No.:261767-91-3
- Denudatine
Catalog No.:BCN5406
CAS No.:26166-37-0
- CGS 35066
Catalog No.:BCC5916
CAS No.:261619-50-5
- Naproxen Sodium
Catalog No.:BCC6490
CAS No.:26159-34-2
- 3alpha-Acetoxy-20-oxo-29-norlupane-23,28-dioic acid
Catalog No.:BCN6507
CAS No.:262272-76-4
- 3,6-Dihydroxy-1,7-dimethoxyxanthone
Catalog No.:BCN6394
CAS No.:262292-34-2
- H-D-Aib-OH
Catalog No.:BCC3151
CAS No.:2623-91-8
- Debenzoylgalloylpaeoniflorin
Catalog No.:BCC8927
CAS No.:262350-51-6
- Mudanpioside J
Catalog No.:BCC9050
CAS No.:262350-52-7
- Torcetrapib
Catalog No.:BCC2330
CAS No.:262352-17-0
- 7,15-Dihydroxypodocarp-8(14)-en-13-one
Catalog No.:BCN1470
CAS No.:262355-96-4
- Cyclofenil
Catalog No.:BCC7839
CAS No.:2624-43-3
- BVD 10
Catalog No.:BCC5882
CAS No.:262418-00-8
- Boc-β-Homo-Pro-OH
Catalog No.:BCC2628
CAS No.:26250-84-0
- Peritassine A
Catalog No.:BCC9117
CAS No.:262601-67-2
- AICAR
Catalog No.:BCC3606
CAS No.:2627-69-2
Synthesis and characterization of time-resolved fluorescence probes for evaluation of competitive binding to melanocortin receptors.[Pubmed:23890524]
Bioorg Med Chem. 2013 Sep 1;21(17):5029-38.
Probes for use in time-resolved fluorescence competitive binding assays at melanocortin receptors based on the parental ligands MSH(4), MSH(7), and NDP-alpha-MSH were prepared by solid phase synthesis methods, purified, and characterized. The saturation binding of these probes was studied using HEK-293 cells engineered to overexpress the human melanocortin 4 receptor (hMC4R) as well as the human cholecystokinin 2 receptor (hCCK2R). The ratios of non-specific binding to total binding approached unity at high concentrations for each probe. At low probe concentrations, receptor-mediated binding and uptake was discernable, and so probe concentrations were kept as low as possible in determining Kd values. The Eu-DTPA-PEGO-MSH(4) probe exhibited low specific binding relative to non-specific binding, even at low nanomolar concentrations, and was deemed unsuitable for use in competition binding assays. The Eu-DTPA-PEGO probes based on MSH(7) and NDP-alpha-MSH exhibited Kd values of 27+/-3.9nM and 4.2+/-0.48nM, respectively, for binding with hMC4R. These probes were employed in competitive binding assays to characterize the interactions of hMC4R with monovalent and divalent MSH(4), MSH(7), and NDP-alpha-MSH constructs derived from squalene. Results from assays with both probes reflected only statistical enhancements, suggesting improper ligand spacing on the squalene scaffold for the divalent constructs. The Ki values from competitive binding assays that employed the MSH(7)-based probe were generally lower than the Ki values obtained when the probe based on NDP-alpha-MSH was employed, which is consistent with the greater potency of the latter probe. The probe based on MSH(7) was also competed with monovalent, divalent, and trivalent MSH(4) constructs that previously demonstrated multivalent binding in competitive binding assays against a variant of the probe based on NDP-alpha-MSH. Results from these assays confirm multivalent binding, but suggest a more modest increase in avidity for these MSH(4) constructs than was previously reported.
N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.[Pubmed:23932788]
Bioorg Med Chem Lett. 2013 Sep 15;23(18):5082-5.
Derivatives of peptides of the TIPP (Tyr-Tic-Phe-Phe; Tic=1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) family containing a guanidino (Guan) function in place of the N-terminal amino group were synthesized in an effort to improve their blood-brain barrier permeability. Unexpectedly, N-terminal amidination significantly altered the in vitro opioid activity profiles. Guan-analogues of TIPP-related delta opioid antagonists showed delta partial agonist or mixed delta partial agonist/mu partial agonist activity. Guanidinylation of the mixed mu agonist/delta antagonists H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2) and H-Dmt-TicPsi[CH2NH]Phe-Phe-NH2 (DIPP-NH2[Psi]) converted them to mixed mu agonist/delta agonists. A docking study revealed distinct positioning of DIPP-NH2 and Guan-DIPP-NH2 in the delta receptor binding site. Lys(3)-analogues of DIPP-NH2 and DIPP-NH2[Psi] (guanidinylated or non-guanidinylated) turned out to be mixed mu/kappa agonists with delta antagonist-, delta partial agonist- or delta full agonist activity. Compounds with some of the observed mixed opioid activity profiles have therapeutic potential as analgesics with reduced side effects or for treatment of cocaine addiction.